Additional Information
Book Details
Abstract
Heart failure is the only cardiovascular disease that is increasing. The impact on the critical care environment and the health care system, as a whole, is significant from both a cost and burden to the system perspective. There are 6.5 million hospital days a year and nearly $40 billion dollars in yearly health care costs attributed to heart failure in the United States. There are more Medicare monies spent for diagnosing and treating heart failure than any other Diagnosis Related Group. There is a 24% hospital re-admission rate for this diagnosis which leads to financial implications for health care systems. The human cost is also significant. Less than half of Americans diagnosed with heart failure survive greater than 5 years. The ongoing health care needs and cost of this chronic disease takes a significant toll on patients’ finances, time and quality of life. Over $2.9 billion dollars is spent annually on the pharmaceutical management of heart failure in the United States. This diagnosis is the leading cause of hospitalization for patients who are 65 years of age and older. Few health care providers in the critical care environment are not affected by heart failure on a routine basis. Caring for these patients and their families is both a challenging and yet a rewarding experience. This edition will provide critical care nurses with a comprehensive heart failure review which is essential in caring for this challenging population given the dynamic health and critical care environments.Â
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front Cover | Cover | ||
Heart Failure\r | i | ||
Copyright\r | ii | ||
Contributors | iii | ||
Consulting Editor | iii | ||
Editors | iii | ||
Authors | iii | ||
Contents | v | ||
Preface: Heart Failure\r | v | ||
Heart Failure: A Primer\r | v | ||
Heart Failure and Atrial Fibrillation\r | v | ||
Hypertensive Crisis: A Review of Pathophysiology and Treatment\r | v | ||
Hemodynamics of Acute Right Heart Failure in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome\r | vi | ||
Mechanisms of Cardiotoxicity and the Development of Heart Failure\r | vi | ||
Characteristics, Complications, and Treatment of Acute Pericarditis\r | vi | ||
High-Output Heart Failure Caused by Thyrotoxicosis and Beriberi\r | vi | ||
Sleep and Heart Failure\r | vii | ||
Patient Safety Coalition: A Focus on Heart Failure\r | vii | ||
The Role of the Nurse Navigator in the Management of the Heart Failure Patient\r | vii | ||
Ventricular Assist Device and Destination Therapy Candidates from Preoperative Selection Through End of Hospitalization\r | vii | ||
Cardiac Transplantation: Considerations for the Intensive Care Unit Nurse\r | viii | ||
Palliative Care in Heart Failure\r | viii | ||
CRITICAL CARE NURSING\rCLINICS OF NORTH AMERICA\r | ix | ||
FORTHCOMING ISSUES | ix | ||
March 2016 | ix | ||
June 2016 | ix | ||
September 2016 | ix | ||
RECENT ISSUES | ix | ||
September 2015 | ix | ||
June 2015 | ix | ||
March 2015 | ix | ||
Preface: Heart Failure \r | xi | ||
Heart Failure | 413 | ||
Key points | 413 | ||
INTRODUCTION | 413 | ||
HEART FAILURE DEFINED | 414 | ||
COMMON CAUSAL PATHWAYS TO HEART FAILURE | 414 | ||
PREVAILING PATHOPHYSIOLOGIC MECHANISMS OF HEART FAILURE | 415 | ||
Neurohormonal Activation | 415 | ||
Inflammation | 416 | ||
DIAGNOSING HEART FAILURE | 417 | ||
History and Physical | 417 | ||
Diagnostics | 417 | ||
Importance of Symptoms in Heart Failure | 418 | ||
HEART FAILURE MANAGEMENT STRATEGIES | 419 | ||
Heart Failure Self-care | 420 | ||
SUMMARY | 421 | ||
REFERENCES | 421 | ||
Heart Failure and Atrial Fibrillation | 427 | ||
Key points | 427 | ||
INTRODUCTION | 427 | ||
THE HEART FAILURE–ATRIAL FIBRILLATION CONNECTION | 427 | ||
ANTICOAGULATION | 429 | ||
RATE CONTROL | 430 | ||
RHYTHM CONTROL | 431 | ||
CARDIOVERSION | 432 | ||
DEVICE THERAPY | 434 | ||
CATHETER ABLATION | 435 | ||
HYBRID ABLATION | 435 | ||
SURGICAL ABLATION | 436 | ||
LEFT ATRIAL APPENDAGE OCCLUSION | 436 | ||
OTHER STRATEGIES | 436 | ||
SUMMARY | 436 | ||
REFERENCES | 437 | ||
Hypertensive Crisis | 439 | ||
Key points | 439 | ||
INTRODUCTION | 439 | ||
DEFINITIONS | 440 | ||
CLINICAL PRESENTATION | 440 | ||
Hypertensive Urgency | 440 | ||
Hypertensive Emergency | 440 | ||
PATHOPHYSIOLOGY | 441 | ||
ETIOLOGY | 442 | ||
PHARMACOLOGIC TREATMENT APPROACH | 446 | ||
Hypertensive Urgency | 446 | ||
Hypertensive Emergency | 446 | ||
SUMMARY | 446 | ||
REFERENCES | 446 | ||
Hemodynamics of Acute Right Heart Failure in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome | 449 | ||
Key points | 449 | ||
INTRODUCTION | 449 | ||
ACUTE RIGHT VENTRICULAR FAILURE | 450 | ||
Pressure Monitoring | 451 | ||
Right Atrial Pressure (Right Atrial or Central Venous Pressure) and Pulmonary Arteriole Occlusion Pressure | 452 | ||
OXYGENATION | 453 | ||
External Respiration | 453 | ||
Internal (Tissue Respiration) | 455 | ||
Compensation in shock | 455 | ||
COMPENSATION | 456 | ||
Acute Cor Pulmonale | 457 | ||
KEY CONCEPTS | 459 | ||
Application of Positive Pressure Ventilation | 460 | ||
The Relationship between Left Ventricular Outflow and Arterial Perfusion Is Dynamic and Interactive | 460 | ||
KEY CONCEPTS | 461 | ||
SUMMARY | 461 | ||
SIMPLE STRATEGIES | 462 | ||
CASE PRESENTATION | 465 | ||
REFERENCES | 466 | ||
Mechanisms of Cardiotoxicity and the Development of Heart Failure | 469 | ||
Key points | 469 | ||
Introduction | 469 | ||
Cancer therapies and cardiotoxicity | 470 | ||
Direct Cardiomyocyte Injury | 470 | ||
Thromboembolic Events | 472 | ||
Hypertension | 472 | ||
Biological agents and heart failure | 473 | ||
Alcoholic cardiomyopathy | 473 | ||
Cocaine and the development of heart failure | 475 | ||
Summary | 478 | ||
References | 478 | ||
Characteristics, Complications, and Treatment of Acute Pericarditis | 483 | ||
Key points | 483 | ||
INTRODUCTION | 483 | ||
STRUCTURE AND FUNCTION OF THE PERICARDIUM | 484 | ||
DEFINITION OF ACUTE PERICARDITIS | 484 | ||
INCIDENCE | 484 | ||
CAUSES | 484 | ||
DIAGNOSIS | 485 | ||
PROGNOSIS | 489 | ||
CLINICAL MANAGEMENT | 489 | ||
Pharmacologic Management | 489 | ||
Nonsteroidal antiinflammatory drugs | 490 | ||
Colchicine | 490 | ||
Systemic corticosteroids | 491 | ||
Heparin | 491 | ||
Exercise Restrictions | 491 | ||
Follow-up Care | 491 | ||
Patient and Family Teaching | 491 | ||
DISEASE COMPLICATIONS | 492 | ||
CURRENT EVIDENCE | 493 | ||
SUMMARY | 496 | ||
REFERENCES | 496 | ||
High-Output Heart Failure Caused by Thyrotoxicosis and Beriberi | 499 | ||
Key points | 499 | ||
INTRODUCTION | 499 | ||
THYROTOXICOSIS | 500 | ||
The Thyroid | 500 | ||
Signs and Symptoms of Thyrotoxicosis | 501 | ||
Diagnosing Thyrotoxicosis-Induced Heart Failure | 502 | ||
Managing Thyrotoxicosis-Induced Heart Failure | 502 | ||
Amiodarone-Induced Thyrotoxicosis | 504 | ||
BERIBERI | 504 | ||
Dry Beriberi | 506 | ||
Wet Beriberi | 506 | ||
About Thiamine | 506 | ||
Signs and Symptoms of Wet Beriberi | 507 | ||
Diagnosing Wet Beriberi | 507 | ||
Treating Wet Beriberi | 507 | ||
CARING FOR THE PATIENT WITH HIGH-OUTPUT HEART FAILURE CAUSED BY THYROTOXICOSIS OR BERIBERI | 508 | ||
SUMMARY | 509 | ||
REFERENCES | 509 | ||
Sleep and Heart Failure | 511 | ||
Key points | 511 | ||
INTRODUCTION | 511 | ||
SLEEP PHYSIOLOGY | 512 | ||
SLEEP-DISORDERED BREATHING | 512 | ||
CONSEQUENCES OF SLEEP-DISORDERED BREATHING ON HEART FAILURE | 513 | ||
IDENTIFYING PATIENTS WITH SLEEP-DISORDERED BREATHING | 514 | ||
TREATMENT OF SLEEP-DISORDERED BREATHING IN HEART FAILURE | 514 | ||
Noninvasive Ventilatory Support | 516 | ||
Positive airway pressure therapy | 516 | ||
Adaptive servo-ventilation therapy | 517 | ||
Supplemental Oxygen | 517 | ||
Cardiac Pacing | 518 | ||
Pharmacologic Interventions | 518 | ||
Miscellaneous | 519 | ||
Oral sleep appliances | 519 | ||
Phrenic nerve stimulation | 519 | ||
CLINICAL IMPLICATIONS | 519 | ||
SUMMARY | 520 | ||
REFERENCES | 520 | ||
Patient Safety Coalition | 523 | ||
Key points | 523 | ||
INTRODUCTION | 523 | ||
BACKGROUND OF PATIENT SAFETY COALITIONS | 524 | ||
TACTICS TO REDUCE READMISSION RATES | 527 | ||
TRANSITIONS OF CARE: HOSPITAL TO SKILLED NURSING FACILITIES | 527 | ||
IMPLEMENTATION OF MINIMUM CARE STANDARDS FOR THE CARE OF PATIENTS WITH HEART FAILURE | 528 | ||
BETTER VERBAL COMMUNICATION | 530 | ||
TRANSITIONS OF CARE: HOSPITAL TO HOME HEALTH CARE | 531 | ||
OUTCOMES | 533 | ||
DISCUSSION | 533 | ||
SUMMARY | 533 | ||
ACKNOWLEDGMENTS | 534 | ||
REFERENCES | 534 | ||
The Role of the Nurse Navigator in the Management of the Heart Failure Patient | 537 | ||
Key points | 537 | ||
THE NURSE NAVIGATOR | 539 | ||
HEART SUCCESS TRANSITION CLINIC | 539 | ||
VIRTUAL HEART SUCCESS TRANSITION CLINIC | 542 | ||
STANDARDIZATION OF PATIENT EDUCATION | 544 | ||
GROUP VISIT MODEL IMPLEMENTATION | 545 | ||
HEART FAILURE NURSE NAVIGATOR | 547 | ||
Job Description | 547 | ||
Position summary | 547 | ||
Patient education | 548 | ||
Patient liaison/advocate | 548 | ||
Outreach | 548 | ||
Assess patient and family needs | 548 | ||
Quality outcome measures | 548 | ||
Professional and staff responsibilities | 549 | ||
REFERENCES | 549 | ||
Ventricular Assist Device and Destination Therapy Candidates from Preoperative Selection Through End of Hospitalization | 551 | ||
Key points | 551 | ||
PULSATILE/CONTINUOUS FLOW PHYSIOLOGY | 552 | ||
PATIENT SELECTION AND PREOPERATIVE CONSIDERATIONS | 554 | ||
Nutrition | 555 | ||
Hemodynamics | 555 | ||
Infection Prevention | 556 | ||
Psychosocial Considerations | 556 | ||
Exclusion Criteria | 556 | ||
INTRAOPERATIVE CONSIDERATIONS | 556 | ||
POSTOPERATIVE CONSIDERATIONS | 558 | ||
Hemodynamics and the Ventricular Assistance Device Patient | 558 | ||
Right Ventricular Function | 559 | ||
Anticoagulation and Bleeding | 560 | ||
Gastrointestinal Bleeding | 560 | ||
Infection Prevention | 561 | ||
Device Management | 562 | ||
PATIENT AND CAREGIVER EDUCATION | 562 | ||
SUMMARY | 563 | ||
REFERENCES | 563 | ||
Cardiac Transplantation | 565 | ||
Key points | 565 | ||
INTRODUCTION | 565 | ||
PREOPERATIVE PREPARATION | 566 | ||
PERIOPERATIVE PERIOD | 568 | ||
POSTOPERATIVE PERIOD | 569 | ||
SUMMARY | 574 | ||
REFERENCES | 574 | ||
Palliative Care in Heart Failure | 577 | ||
Key points | 577 | ||
HEART FAILURE BACKGROUND | 577 | ||
WHAT IS PALLIATIVE CARE? | 578 | ||
COMPLEXITIES OF HEART FAILURE AND PALLIATIVE CARE | 579 | ||
Heart Failure Illness Trajectory: Unpredictable Course | 579 | ||
Failure to Have the Conversation | 579 | ||
Lack of Understanding of Palliative Care as an Overarching Philosophy Encompassing Hospice | 580 | ||
Lack of Available Services/Teams | 581 | ||
BASIC PALLIATIVE CARE FOR HEART FAILURE | 581 | ||
FUTURE DIRECTION OF PALLIATIVE CARE IN HEART FAILURE | 584 | ||
REFERENCES | 585 |